RecruitingNCT06649565

Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy


Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

300 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Breast cancer has become the world's number one cancer. While its therapeutic efficacy is increasing, how to achieve non-invasive evaluation of the efficacy of neoadjuvant therapy (NAT) for breast cancer patients and thus avoid surgery has become a bottleneck problem that needs to be broken through in clinical diagnosis and treatment. Existing non-invasive evaluation strategies are limited to single-center, single-modality modeling, and have problems such as low performance and poor versatility. Therefore, in the early stage of this study, multi-modality breast cancer patient data from multiple centers across the country were collected and the establishment of an artificial intelligence (AI) efficacy prediction model was preliminarily completed. On this basis, this project intends to further improve the multi-center prospective validation study of the prediction model. The research results will help solve the scientific problem of non-invasive judgment of NAT efficacy in breast cancer patients and provide a new paradigm for the research of high-performance AI diagnosis and treatment auxiliary systems applicable to multiple centers.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is validating an AI-powered model that uses MRI scans to predict whether breast cancer patients who receive chemotherapy before surgery (neoadjuvant therapy) will achieve a complete response — meaning no cancer cells are detectable when the tissue is examined after surgery. This could help doctors make more personalized surgical decisions. **You may be eligible if...** - You are 18 or older and female - You have confirmed invasive breast cancer (stage I–III) - You received chemotherapy before surgery (neoadjuvant treatment) - You have MRI scans taken before and after neoadjuvant therapy - You underwent breast-conserving surgery or mastectomy after treatment - Your postoperative tissue examination results are available **You may NOT be eligible if...** - You have cancer in both breasts, multiple lesions, or hidden (occult) breast cancer - Your MRI imaging quality is poor - You had other cancer treatments before enrollment - You have another active cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERno intervention

no intervention


Locations(2)

Sanhuan Cancer Hospital, Chaoyang District, Beijing(Cancer Hospital, Chinese Academy of Medical Sciences, close medical alliance)

Beijing, Beijing Municipality, China

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06649565


Related Trials